{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:27:26Z","timestamp":1792736846991,"version":"4.5.0"},"reference-count":238,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Neuroscience"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.mcn.2025.104010","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T11:29:11Z","timestamp":1746530951000},"page":"104010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["RNA-based therapies for neurodegenerative disease: Targeting molecular mechanisms for disease modification"],"prefix":"10.1016","volume":"133","author":[{"given":"Vishal","family":"Bhati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonima","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Kabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.mcn.2025.104010_bb0005","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1161\/CIRCRESAHA.111.247437","article-title":"Differential expression of microRNAs in different disease states","volume":"110","author":"Abdellatif","year":"2012","journal-title":"Circ. Res."},{"key":"10.1016\/j.mcn.2025.104010_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-017-0101-9","article-title":"RNAi mechanisms in Huntington\u2019s disease therapy: siRNA versus shRNA","volume":"6","author":"Aguiar","year":"2017","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.mcn.2025.104010_bb0015","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12551-017-0392-1","article-title":"Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer","volume":"10","author":"Ahmadzada","year":"2018","journal-title":"Biophys. Rev."},{"issue":"1","key":"10.1016\/j.mcn.2025.104010_bb0020","article-title":"Blood-brain barrier overview: structural and functional correlation","volume":"2021","author":"Alahmari","year":"2021","journal-title":"Neural Plast."},{"issue":"2","key":"10.1016\/j.mcn.2025.104010_bb0025","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ymthe.2017.11.015","article-title":"Selective \u03b1-synuclein knockdown in monoamine neurons by intranasal oligonucleotide delivery: potential therapy for Parkinson\u2019s disease","volume":"26","author":"Alarc\u00f3n-Ar\u00eds","year":"2018","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.mcn.2025.104010_bb0030","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s12951-023-02147-z","article-title":"Engineering siRNA therapeutics: challenges and strategies","volume":"21","author":"Ali Zaidi","year":"2023","journal-title":"J. Nanobiotechnol."},{"issue":"11","key":"10.1016\/j.mcn.2025.104010_bb0035","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.2174\/1570159X19666210402104054","article-title":"siRNA therapeutics: future promise for neurodegenerative diseases","volume":"19","author":"Amiri","year":"2021","journal-title":"Curr. Neuropharmacol."},{"issue":"4","key":"10.1016\/j.mcn.2025.104010_bb0040","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1158\/1078-0432.CCR-20-3139","article-title":"Cobomarsen, an oligonucleotide inhibitor of miR-155, slows DLBCL tumor cell growth in vitro and in vivo","volume":"27","author":"Anastasiadou","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.mcn.2025.104010_bb0045","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1021\/acschemneuro.1c00295","article-title":"APOE genotype and Alzheimer\u2019s disease: the influence of lifestyle and environmental factors","volume":"12","author":"Angelopoulou","year":"2021","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.mcn.2025.104010_bb0050","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.60","article-title":"Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy","volume":"3","author":"Armbruster","year":"2016","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"issue":"11","key":"10.1016\/j.mcn.2025.104010_bb0055","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/mds.26020","article-title":"Huntingtin-lowering strategies in Huntington\u2019s disease: antisense oligonucleotides, small RNAs, and gene editing","volume":"29","author":"Aronin","year":"2014","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.mcn.2025.104010_bb0060","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/17425247.2022.2063835","article-title":"Current progress of miRNA-derivative nucleotide drugs: modifications, delivery systems, applications","volume":"19","author":"Asakiya","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.mcn.2025.104010_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.155272","article-title":"Neuroprotective potentials of Lead phytochemicals against Alzheimer\u2019s disease with focus on oxidative stress-mediated signaling pathways: pharmacokinetic challenges, target specificity, clinical trials and future perspectives","volume":"124","author":"Ayaz","year":"2024","journal-title":"Phytomedicine"},{"issue":"16","key":"10.1016\/j.mcn.2025.104010_bb0070","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2217\/nnm.14.162","article-title":"Strategies to antagonize miRNA functions in vitro and in vivo","volume":"9","author":"Baigude","year":"2014","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.mcn.2025.104010_bb0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/cells9010137","article-title":"RNA-based therapeutics: from antisense oligonucleotides to miRNAs","volume":"9","author":"Bajan","year":"2020","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.mcn.2025.104010_bb0080","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.mcn.2025.104010_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/biology12101334","article-title":"MicroRNAs: small but key players in viral infections and immune responses to viral pathogens","volume":"12","author":"Bauer","year":"2023","journal-title":"Biology"},{"issue":"3","key":"10.1016\/j.mcn.2025.104010_bb0090","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/1566523220999200817164051","article-title":"Gene therapy in the management of Parkinson\u2019s disease: potential of GDNF as a promising therapeutic strategy","volume":"20","author":"Behl","year":"2020","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.mcn.2025.104010_bb0095","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.mcn.2025.104010_bb0100","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1146\/annurev-pharmtox-010919-023738","article-title":"Antisense drugs make sense for neurological diseases","volume":"61","author":"Bennett","year":"2021","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.mcn.2025.104010_bb0105","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bph.17302","article-title":"Mitigating off-target effects of small RNAs: conventional approaches, network theory and artificial intelligence","volume":"182","author":"Bereczki","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.mcn.2025.104010_bb0440","article-title":"New data from Biogen's investigational antisense oligonucleotide (ASO) study","year":"2025","journal-title":"Biogen"},{"issue":"5","key":"10.1016\/j.mcn.2025.104010_bb0110","article-title":"Mechanisms tailoring the expression of heat shock proteins to proteostasis challenges","volume":"298","author":"Boopathy","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mcn.2025.104010_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107873","article-title":"Oligonucleotides as therapeutic tools for brain disorders: focus on major depressive disorder and Parkinson\u2019s disease","volume":"227","author":"Bortolozzi","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.mcn.2025.104010_bb0120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41568-022-00541-7","article-title":"RNA splicing dysregulation and the hallmarks of cancer","volume":"23","author":"Bradley","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"17\u201318","key":"10.1016\/j.mcn.2025.104010_bb0125","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1089\/hum.2024.113","article-title":"Advances in MicroRNA therapeutics: from preclinical to clinical studies","volume":"35","author":"Brillante","year":"2024","journal-title":"Hum. Gene Ther."},{"issue":"3","key":"10.1016\/j.mcn.2025.104010_bb0130","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/brain\/awab423","article-title":"Antisense therapies in neurological diseases","volume":"145","author":"Brunet de Courssou","year":"2022","journal-title":"Brain"},{"issue":"8","key":"10.1016\/j.mcn.2025.104010_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/genes13081370","article-title":"Appraisal for the potential of viral and nonviral vectors in gene therapy: a review","volume":"13","author":"Butt","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.mcn.2025.104010_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13041-020-00656-8","article-title":"LncRNA MALAT1 facilitates inflammasome activation via epigenetic suppression of Nrf2 in Parkinson\u2019s disease","volume":"13","author":"Cai","year":"2020","journal-title":"Mol. Brain"},{"issue":"3","key":"10.1016\/j.mcn.2025.104010_bb0145","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.mcn.2025.104010_bb0150","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.neuroscience.2018.07.019","article-title":"Long noncoding RNA SNHG1 promotes neuroinflammation in Parkinson\u2019s disease via regulating miR-7\/NLRP3 pathway","volume":"388","author":"Cao","year":"2018","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/j.mcn.2025.104010_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9030303","article-title":"Oligonucleotide-based therapies for renal diseases","volume":"9","author":"Carton-Garcia","year":"2021","journal-title":"Biomedicines"},{"issue":"7228","key":"10.1016\/j.mcn.2025.104010_bb0160","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nature07758","article-title":"The promises and pitfalls of RNA-interference-based therapeutics","volume":"457","author":"Castanotto","year":"2009","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.mcn.2025.104010_bb0165","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nrd.2018.136","article-title":"Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs","volume":"17","author":"Charvin","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.mcn.2025.104010_bb0170","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1089\/dna.2006.0549","article-title":"MicroRNA detection and target prediction: integration of computational and experimental approaches","volume":"26","author":"Chaudhuri","year":"2007","journal-title":"DNA Cell Biol."},{"issue":"1","key":"10.1016\/j.mcn.2025.104010_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2019.e01167","article-title":"The microRNA and the perspectives of miR-302","volume":"5","author":"Chen","year":"2019","journal-title":"Heliyon"},{"issue":"5","key":"10.1016\/j.mcn.2025.104010_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16050674","article-title":"Novel drug delivery systems: an important direction for drug innovation research and development","volume":"16","author":"Chen","year":"2024","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.mcn.2025.104010_bb0185","doi-asserted-by":"crossref","first-page":"35","DOI":"10.14304\/SURYA.JPR.V4N7.5","article-title":"RNA therapeutics: RNAi and antisense mechanisms and clinical applications","volume":"4","author":"Chery","year":"2016","journal-title":"Postdoc J."},{"issue":"2","key":"10.1016\/j.mcn.2025.104010_bb0190","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/nat.2016.0656","article-title":"Molecular mechanisms of antisense oligonucleotides","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Ther."},{"issue":"10","key":"10.1016\/j.mcn.2025.104010_bb0195","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","article-title":"Phosphorothioate modified oligonucleotide-protein interactions","volume":"48","author":"Crooke","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.mcn.2025.104010_bb0200","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41392-022-01175-9","article-title":"RNA modifications: importance in immune cell biology and related diseases","volume":"7","author":"Cui","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.mcn.2025.104010_bb0205","article-title":"Alzheimer's disease drug development pipeline: 2022","volume":"8","author":"Cummings","year":"2022","journal-title":"Alzheimer's Dement.: Transl. Res. Clin. Interv."},{"issue":"1","key":"10.1016\/j.mcn.2025.104010_bb0210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrg2916","article-title":"Small RNA sorting: matchmaking for Argonautes","volume":"12","author":"Czech","year":"2011","journal-title":"Nat. Rev. Genet."},{"issue":"8","key":"10.1016\/j.mcn.2025.104010_bb0215","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrendo.2011.57","article-title":"RNAi-based therapeutic strategies for metabolic disease","volume":"7","author":"Czech","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"issue":"13","key":"10.1016\/j.mcn.2025.104010_bb0220","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.addr.2012.08.014","article-title":"RNAi-based nanomedicines for targeted personalized therapy","volume":"64","author":"Daka","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.mcn.2025.104010_bb0225","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1261\/rna.038596.113","article-title":"Reflections on the history of pre-mRNA processing and highlights of current knowledge: a unified picture","volume":"19","author":"Darnell","year":"2013","journal-title":"RNA"},{"key":"10.1016\/j.mcn.2025.104010_bb0230","article-title":"Enhancing siRNA cancer therapy: multifaceted strategies with lipid and polymer-based carrier systems","volume":"124545","author":"Dastgerdi","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.mcn.2025.104010_bb0235","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1007\/s10571-023-01408-7","article-title":"Pathophysiological aspects and therapeutic armamentarium of Alzheimer\u2019s disease: recent trends and future development","volume":"43","author":"Dave","year":"2023","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.mcn.2025.104010_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115283","article-title":"RNA therapies for CNS diseases","volume":"208","author":"Di Francesco","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.mcn.2025.104010_bb0245","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tig.2022.02.006","article-title":"Emerging concepts of miRNA therapeutics: from cells to clinic","volume":"38","author":"Diener","year":"2022","journal-title":"Trends Genet."},{"key":"10.1016\/j.mcn.2025.104010_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1556-276X-9-252","article-title":"A sight on the current nanoparticle-based gene delivery vectors","volume":"9","author":"Dizaj","year":"2014","journal-title":"Nanoscale Res. Lett."},{"issue":"2","key":"10.1016\/j.mcn.2025.104010_bb0255","article-title":"Repurposed drugs, molecular vaccines, immune-modulators, and nanotherapeutics to treat and prevent COVID-19 associated with SARS-CoV-2, a deadly nanovector","volume":"4","author":"Dube","year":"2021","journal-title":"Adv. Ther."},{"issue":"12","key":"10.1016\/j.mcn.2025.104010_bb0260","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","article-title":"Exploratory tau biomarker results from a multiple ascending-dose study of BIIB080 in Alzheimer disease: a randomized clinical trial","volume":"80","author":"Edwards","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.mcn.2025.104010_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113609","article-title":"LncRNA-miRNA axis in tumor progression and therapy response: an emphasis on molecular interactions and therapeutic interventions","volume":"154","author":"Entezari","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.mcn.2025.104010_bb0270","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/ph10030063","article-title":"Nanofiber scaffolds as drug delivery systems to bridge spinal cord injury","volume":"10","author":"Faccendini","year":"2017","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.mcn.2025.104010_bb0275","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.7150\/ijbs.87741","article-title":"A review on Gaucher disease: therapeutic potential of \u03b2-glucocerebrosidase-targeted mRNA\/saRNA approach","volume":"20","author":"Feng","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.mcn.2025.104010_bb0280","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.bbi.2021.08.230","article-title":"LncRNA 4344 promotes NLRP3-related neuroinflammation and cognitive impairment by targeting miR-138-5p","volume":"98","author":"Feng","year":"2021","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.mcn.2025.104010_bb0285","article-title":"miRNA nanoencapsulation to regulate the programming of the blood-brain barrier permeability by hipoxia","volume":"3","author":"Figueroa Becerra","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov. (CRPHAR, 2022)"},{"key":"10.1016\/j.mcn.2025.104010_bb0290","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.sbi.2005.05.006","article-title":"Post transcriptional gene silencing by siRNAs and miRNAs","volume":"15","author":"Filipowicz","year":"2005","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"18","key":"10.1016\/j.mcn.2025.104010_bb0295","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.mcn.2025.104010_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252111658","article-title":"Epigenetic explorations of neurological disorders, the identification methods, and therapeutic avenues","volume":"25","author":"Firdaus","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"6669","key":"10.1016\/j.mcn.2025.104010_bb0305","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.mcn.2025.104010_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2023.148674","article-title":"Potential biomaterials and experimental animal models for inventing new drug delivery approaches in the neurodegenerative disorder: multiple sclerosis","volume":"1822","author":"Gadhave","year":"2024","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.mcn.2025.104010_bb0315","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1515\/revneuro-2016-0035","article-title":"Protein misfolding and aggregation in neurodegenerative diseases: a review of pathogeneses, novel detection strategies, and potential therapeutics","volume":"30","author":"Gandhi","year":"2019","journal-title":"Rev. Neurosci."},{"issue":"9","key":"10.1016\/j.mcn.2025.104010_bb0320","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/mt.2008.144","article-title":"Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic","volume":"16","author":"Giering","year":"2008","journal-title":"Mol. Ther."},{"issue":"11","key":"10.1016\/j.mcn.2025.104010_bb0325","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/14728222.2018.1535594","article-title":"Let-7 microRNA as a potential therapeutic target with implications for immunotherapy","volume":"22","author":"Gilles","year":"2018","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.mcn.2025.104010_bb0330","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.914430","article-title":"RISC-y business: limitations of short hairpin RNA-mediated gene silencing in the brain and a discussion of CRISPR\/Cas-based alternatives","volume":"15","author":"Goel","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.mcn.2025.104010_bb0335","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.937133","article-title":"Neuronal cell death mechanisms in Alzheimer\u2019s disease: an insight","volume":"15","author":"Goel","year":"2022","journal-title":"Front. Mol. Neurosci."},{"issue":"8","key":"10.1016\/j.mcn.2025.104010_bb0340","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.3390\/ijms140816010","article-title":"Non-coding RNAs: multi-tasking molecules in the cell","volume":"14","author":"Gomes","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mcn.2025.104010_bb0345","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.arr.2015.03.001","article-title":"siRNA as a tool to improve the treatment of brain diseases: mechanism, targets and delivery","volume":"21","author":"Gomes","year":"2015","journal-title":"Ageing Res. Rev."},{"issue":"35","key":"10.1016\/j.mcn.2025.104010_bb0350","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.2174\/1381612822666160720163656","article-title":"Strategies that target tight junctions for enhanced drug delivery","volume":"22","author":"Gonz\u00e1lez-Mariscal","year":"2016","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.mcn.2025.104010_bb0355","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020371","article-title":"Emerging therapeutic strategies for Parkinson\u2019s disease and future prospects: A 2021 update","volume":"10","author":"Gouda","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.mcn.2025.104010_bb0360","series-title":"Methods in Enzymology","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0076-6879(04)92023-X","article-title":"Adeno-associated virus vectors for short hairpin RNA expression","volume":"Vol. 392","author":"Grimm","year":"2005"},{"issue":"1\u20132","key":"10.1016\/j.mcn.2025.104010_bb0365","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0006-8993(99)02089-2","article-title":"Comparison of cytosine arabinoside delivery to rat brain by intravenous, intrathecal, intraventricular and intraparenchymal routes of administration","volume":"856","author":"Groothuis","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.mcn.2025.104010_bb0370","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2147\/IJN.S237544","article-title":"Aptamers as versatile ligands for biomedical and pharmaceutical applications","author":"Guan","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.mcn.2025.104010_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.796012","article-title":"Shaping the innate immune response through post-transcriptional regulation of gene expression mediated by RNA-binding proteins","volume":"12","author":"Guillemin","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.mcn.2025.104010_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2025.1547025","article-title":"mRNA vaccine platforms: linking infectious disease prevention and cancer immunotherapy","volume":"13","author":"Haghmorad","year":"2025","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"15","key":"10.1016\/j.mcn.2025.104010_bb0385","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1016\/j.biomaterials.2014.02.027","article-title":"Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy","volume":"35","author":"Han","year":"2014","journal-title":"Biomaterials"},{"issue":"10","key":"10.1016\/j.mcn.2025.104010_bb0390","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13101694","article-title":"RNA-based therapeutics: current developments in targeted molecular therapy of triple-negative breast cancer","volume":"13","author":"Haque","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.mcn.2025.104010_bb0395","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/pharmaceutics14010165","article-title":"Non-viral delivery of RNA gene therapy to the central nervous system","volume":"14","author":"Hauck","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1\u20132","key":"10.1016\/j.mcn.2025.104010_bb0400","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ijpharm.2009.11.006","article-title":"Non-viral gene delivery carrier and its three-dimensional transfection system","volume":"386","author":"He","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.mcn.2025.104010_bb0405","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s00299-016-1933-y","article-title":"Efficient and specific inhibition of plant microRNA function by anti-microRNA oligonucleotides (AMOs) in vitro and in vivo","volume":"35","author":"He","year":"2016","journal-title":"Plant Cell Rep."},{"issue":"1","key":"10.1016\/j.mcn.2025.104010_bb0410","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-41799-1","article-title":"Secondary structures that regulate mRNA translation provide insights for ASO-mediated modulation of cardiac hypertrophy","volume":"14","author":"Hedaya","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mcn.2025.104010_bb0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13578-021-00650-0","article-title":"Exosomal delivery of therapeutic modulators through the blood-brain barrier; promise and pitfalls","volume":"11","author":"Heidarzadeh","year":"2021","journal-title":"Cell Biosci."},{"key":"10.1016\/j.mcn.2025.104010_bb0420","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10577-013-9392-6","article-title":"Epigenetic regulation by long noncoding RNAs in plants","volume":"21","author":"Heo","year":"2013","journal-title":"Chromosome Res."},{"issue":"9","key":"10.1016\/j.mcn.2025.104010_bb0425","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2174\/1381612822666151221150733","article-title":"Evolving drug delivery strategies to overcome the blood brain barrier","volume":"22","author":"Hersh","year":"2016","journal-title":"Curr. Pharm. Des."},{"issue":"12","key":"10.1016\/j.mcn.2025.104010_bb0430","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.mcn.2025.104010_bb0445","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2024.1374843","article-title":"Regulatory role of RNA-binding proteins in microRNA biogenesis","volume":"11","author":"Hynes","year":"2024","journal-title":"Front. Mol. Biosci."},{"issue":"11","key":"10.1016\/j.mcn.2025.104010_bb0450","doi-asserted-by":"crossref","first-page":"9529","DOI":"10.1007\/s11033-023-08749-y","article-title":"Advances in siRNA delivery approaches in cancer therapy: challenges and opportunities","volume":"50","author":"Isazadeh","year":"2023","journal-title":"Mol. Biol. Rep."},{"issue":"1","key":"10.1016\/j.mcn.2025.104010_bb0455","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrd3010","article-title":"Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application","volume":"9","author":"Jackson","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.mcn.2025.104010_bb0460","series-title":"Drug Delivery Systems","first-page":"1","article-title":"Drug delivery systems-an overview","author":"Jain","year":"2008"},{"key":"10.1016\/j.mcn.2025.104010_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114000","article-title":"Messenger RNA-based vaccines: past, present, and future directions in the context of the COVID-19 pandemic","volume":"179","author":"Jain","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mcn.2025.104010_bb0470","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.769184","article-title":"Molecular strategies to target protein aggregation in Huntington\u2019s disease","volume":"8","author":"Jarosi\u0144ska","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.mcn.2025.104010_bb0475","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.929290","article-title":"Non-coding RNAs: the neuroinflammatory regulators in neurodegenerative diseases","volume":"13","author":"Jiang","year":"2022","journal-title":"Front. Neurol."},{"issue":"9","key":"10.1016\/j.mcn.2025.104010_bb0480","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.4103\/NRR.NRR-D-24-00303","article-title":"Nanocarrier-mediated siRNA delivery: a new approach for the treatment of traumatic brain injury\u2013related Alzheimer\u2019s disease","volume":"20","author":"Jin","year":"2025","journal-title":"Neural Regen. Res."},{"issue":"7228","key":"10.1016\/j.mcn.2025.104010_bb0485","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature07755","article-title":"A three-dimensional view of the molecular machinery of RNA interference","volume":"457","author":"Jinek","year":"2009","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.mcn.2025.104010_bb0490","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.bbagen.2013.10.035","article-title":"Evolutionary conservation of long non-coding RNAs; sequence, structure, function","volume":"1840","author":"Johnsson","year":"2014","journal-title":"Biochim. Biophys. Acta - Gen. Subj."},{"issue":"38","key":"10.1016\/j.mcn.2025.104010_bb0495","doi-asserted-by":"crossref","first-page":"27068","DOI":"10.1074\/jbc.M113.486076","article-title":"Expanded polyglutamine-containing N-terminal huntingtin fragments are entirely degraded by mammalian proteasomes","volume":"288","author":"Juenemann","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"14","key":"10.1016\/j.mcn.2025.104010_bb0500","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.mcn.2025.104010_bb0505","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/14737175.2024.2314183","article-title":"Emerging antibody-based therapies for Huntington\u2019s disease: current status and perspectives for future development","volume":"24","author":"Jurcau","year":"2024","journal-title":"Expert Rev. Neurother."},{"issue":"2","key":"10.1016\/j.mcn.2025.104010_bb0510","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijpharm.2015.10.058","article-title":"Recent advances in superparamagnetic iron oxide nanoparticles (SPIONs) for in vitro and in vivo cancer nanotheranostics","volume":"496","author":"Kandasamy","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.mcn.2025.104010_bb0515","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/s41386-022-01311-7","article-title":"Nanoparticle delivery systems for substance use disorder","volume":"47","author":"Kasina","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.mcn.2025.104010_bb0520","first-page":"121","article-title":"Advancing treatments for transthyretin amyloid cardiomyopathy: innovations in RNA silencing, gene editing, TTR stabilization, and degradation","volume":"83","author":"Keller","year":"2025","journal-title":"Pol. Heart J. (Kardiol. Polska)"},{"issue":"9","key":"10.1016\/j.mcn.2025.104010_bb0525","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/17425247.2023.2251890","article-title":"siRNA therapeutics: insights, challenges, remedies and future prospects","volume":"20","author":"Khan","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.mcn.2025.104010_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114338","article-title":"Intrathecal delivery and its applications in leptomeningeal disease","volume":"186","author":"Khang","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mcn.2025.104010_bb0540","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.643681","article-title":"Nucleic acid-based therapeutics in orphan neurological disorders: recent developments","volume":"8","author":"Khorkova","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"23","key":"10.1016\/j.mcn.2025.104010_bb0545","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316933","article-title":"Nucleic acid-based approaches to tackle KRAS mutant cancers","volume":"24","author":"Kim","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.mcn.2025.104010_bb0550","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/d41573-021-00088-6","article-title":"Double setback for ASO trials in Huntington disease","volume":"20","author":"Kingwell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.mcn.2025.104010_bb0555","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1021\/bi401677d","article-title":"Understanding the effect of locked nucleic acid and 2\u2032-O-methyl modification on the hybridization thermodynamics of a miRNA\u2013mRNA pair in the presence and absence of AfPiwi protein","volume":"53","author":"Kumar","year":"2014","journal-title":"Biochemistry"},{"issue":"584","key":"10.1016\/j.mcn.2025.104010_bb0560","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb3945","article-title":"A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma","volume":"13","author":"Kumthekar","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"10.1016\/j.mcn.2025.104010_bb0565","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031851","article-title":"A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics","volume":"23","author":"Lamptey","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.mcn.2025.104010_bb0570","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/wrna.1148","article-title":"Mutual relationships between transcription and pre-mRNA processing in the synthesis of mRNA","volume":"4","author":"Lenasi","year":"2013","journal-title":"Wiley Interdiscip. Rev.: RNA"},{"issue":"19","key":"10.1016\/j.mcn.2025.104010_bb0575","doi-asserted-by":"crossref","first-page":"6424","DOI":"10.1093\/nar\/gkm664","article-title":"Crystal structure, stability and in vitro RNAi activity of oligoribonucleotides containing the ribo-difluorotoluyl nucleotide: insights into substrate requirements by the human RISC Ago2 enzyme","volume":"35","author":"Li","year":"2007","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.mcn.2025.104010_bb0580","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.37175\/stemedicine.v1i4.63","article-title":"Misfolded protein aggregation and altered cellular pathways in neurodegenerative diseases","volume":"1","author":"Li","year":"2020","journal-title":"STEMedicine"},{"key":"10.1016\/j.mcn.2025.104010_bb0585","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.101878","article-title":"lncRNA NEAT1: key player in neurodegenerative diseases","volume":"86","author":"Li","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.mcn.2025.104010_bb0590","doi-asserted-by":"crossref","DOI":"10.3389\/frhem.2024.1468952","article-title":"Recent advancements in gene therapy for sickle cell disease and \u03b2-thalassemia","volume":"3","author":"Li","year":"2024","journal-title":"Front. Hematol."},{"issue":"1","key":"10.1016\/j.mcn.2025.104010_bb0600","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/1061186X.2016.1184272","article-title":"Nano carriers for drug transport across the blood-brain barrier","volume":"25","author":"Li","year":"2017","journal-title":"J. Drug Target."},{"issue":"5","key":"10.1016\/j.mcn.2025.104010_bb0605","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1089\/dna.2006.0551","article-title":"Principles and limitations of computational microRNA gene and target finding","volume":"26","author":"Lindow","year":"2007","journal-title":"DNA Cell Biol."},{"issue":"11","key":"10.1016\/j.mcn.2025.104010_bb0610","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11110598","article-title":"Perivascular and perineural pathways involved in brain delivery and distribution of drugs after intranasal administration","volume":"11","author":"Lochhead","year":"2019","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.mcn.2025.104010_bb0615","doi-asserted-by":"crossref","first-page":"537","DOI":"10.2174\/138920210793175895","article-title":"MicroRNA: biogenesis, function and role in cancer","volume":"11","author":"MacFarlane","year":"2010","journal-title":"Curr. Genomics"},{"issue":"2","key":"10.1016\/j.mcn.2025.104010_bb0620","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1002917","article-title":"The vast, conserved mammalian lincRNome","volume":"9","author":"Managadze","year":"2013","journal-title":"PLoS Comput. Biol."},{"issue":"3","key":"10.1016\/j.mcn.2025.104010_bb0625","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2174\/1871524922666220929153215","article-title":"Neuroinflammation: molecular mechanisms and therapeutic perspectives","volume":"22","author":"Marino","year":"2022","journal-title":"Cent. Nerv. Syst. Agents Med. Chem. - Cent. Nerv. Syst. Agents"},{"key":"10.1016\/j.mcn.2025.104010_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108352","article-title":"Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease","volume":"190","author":"Marucci","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.mcn.2025.104010_bb0635","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jneuroim.2018.11.013","article-title":"Malat1 long noncoding RNA regulates inflammation and leukocyte differentiation in experimental autoimmune encephalomyelitis","volume":"328","author":"Masoumi","year":"2019","journal-title":"J. Neuroimmunol."},{"issue":"5","key":"10.1016\/j.mcn.2025.104010_bb0640","doi-asserted-by":"crossref","first-page":"899","DOI":"10.3233\/JPD-240272","article-title":"Parkinson\u2019s disease drug therapies in the clinical trial pipeline: 2024 update","volume":"14","author":"McFarthing","year":"2024","journal-title":"J. Parkinsons Dis."},{"issue":"9","key":"10.1016\/j.mcn.2025.104010_bb0645","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.2174\/1871527313666140806142955","article-title":"The paths to neurodegeneration in genetic Parkinson's disease","volume":"13","author":"ME Abdel-Salam","year":"2014","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"issue":"23","key":"10.1016\/j.mcn.2025.104010_bb0650","doi-asserted-by":"crossref","first-page":"13301","DOI":"10.1021\/acs.chemrev.4c00472","article-title":"Technologies for Targeted RNA degradation and induced RNA decay","volume":"124","author":"Mikutis","year":"2024","journal-title":"Chem. Rev."},{"key":"10.1016\/j.mcn.2025.104010_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154725","article-title":"The emerging role of miRNA-122 in infectious diseases: mechanisms and potential biomarkers","volume":"249","author":"Mirzaei","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.mcn.2025.104010_bb0660","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e14652","article-title":"Effect on tumor growth by TGF-\u03b21\/COX-2 siRNA combination product (STP705) in a human cholangiocarcinoma (HuCCT-1) xenograft tumor model in nude mice","volume":"37","author":"Molyneaux","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.mcn.2025.104010_bb0665","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.977411","article-title":"Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer\u2019s disease","volume":"14","author":"Mumtaz","year":"2022","journal-title":"Front. Aging Neurosci."},{"issue":"16","key":"10.1016\/j.mcn.2025.104010_bb0670","doi-asserted-by":"crossref","DOI":"10.3390\/cells11162517","article-title":"Signaling by LncRNAs: structure, cellular homeostasis, and disease pathology","volume":"11","author":"Nadhan","year":"2022","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.mcn.2025.104010_bb0675","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23094718","article-title":"MicroRNA alteration, application as biomarkers, and therapeutic approaches in neurodegenerative diseases","volume":"23","author":"Nguyen","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.mcn.2025.104010_bb0680","first-page":"29","article-title":"A brief review on the role of vesicular monoamine transporter2 inhibitors in hyperkinetic movement disorders","volume":"15","author":"Nikkhah","year":"2021","journal-title":"Iran. J. Child Neurol."},{"issue":"4","key":"10.1016\/j.mcn.2025.104010_bb0685","doi-asserted-by":"crossref","DOI":"10.1002\/elan.202300216","article-title":"Electrospun nanofibers synthesis enhancing the activity of energy storage devices\/electrochemical and biosensor applications","volume":"36","author":"Noor","year":"2024","journal-title":"Electroanalysis"},{"issue":"7","key":"10.1016\/j.mcn.2025.104010_bb0690","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/humu.21277","article-title":"Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update","volume":"31","author":"Nuytemans","year":"2010","journal-title":"Hum. Mutat."},{"issue":"1","key":"10.1016\/j.mcn.2025.104010_bb0695","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/1389450119666180703145410","article-title":"Lipid-based nanocarriers for siRNA delivery: challenges, strategies and the lessons learned from the DODAX: MO liposomal system","volume":"20","author":"Oliveira","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.mcn.2025.104010_bb0700","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.1024004","article-title":"Epidemiology of neurodegenerative diseases in the East African region: A meta-analysis","volume":"13","author":"Onohuean","year":"2022","journal-title":"Front. Neurol."},{"issue":"32","key":"10.1016\/j.mcn.2025.104010_bb0705","doi-asserted-by":"crossref","first-page":"20432","DOI":"10.1039\/D2RA01999J","article-title":"Beyond GalNAc! Drug delivery systems comprising complex oligosaccharides for targeted use of nucleic acid therapeutics","volume":"12","author":"O\u2019Sullivan","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.mcn.2025.104010_bb0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.dscb.2025.100187","article-title":"Exploring the role of neuromodulation in neurodegenerative disorders: insights from Alzheimer\u2019s and Parkinson\u2019s diseases","volume":"17","author":"Oyovwi","year":"2025","journal-title":"Brain Disord."},{"key":"10.1016\/j.mcn.2025.104010_bb0715","series-title":"MicroRNA in Human Infectious Diseases","first-page":"3","article-title":"Paradigms in miRNA biogenesis pathways","author":"Panda","year":"2024"},{"issue":"8","key":"10.1016\/j.mcn.2025.104010_bb0720","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1128\/JVI.02383-06","article-title":"Molecular bases of viral RNA targeting by viral small interfering RNA-programmed RISC","volume":"81","author":"Pantaleo","year":"2007","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.mcn.2025.104010_bb0725","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21114007","article-title":"From the argonauts mythological sailors to the argonautes RNA-silencing navigators: their emerging roles in human-cell pathologies","volume":"21","author":"Pantazopoulou","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.mcn.2025.104010_bb0730","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119527","article-title":"Precision editing as a therapeutic approach for \u03b2-hemoglobinopathies","volume":"24","author":"Paschoudi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.mcn.2025.104010_bb0735","doi-asserted-by":"crossref","DOI":"10.3390\/cells9071698","article-title":"Current status of microRNA-based therapeutic approaches in neurodegenerative disorders","volume":"9","author":"Paul","year":"2020","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.mcn.2025.104010_bb0740","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1177\/154405910808701109","article-title":"siRNA, miRNA, and shRNA: in vivo applications","volume":"87","author":"Pushparaj","year":"2008","journal-title":"J. Dent. Res."},{"key":"10.1016\/j.mcn.2025.104010_bb0750","series-title":"microRNA: Medical Evidence: From Molecular Biology to Clinical Practice","first-page":"85","article-title":"microRNAs and neurodegenerative diseases","author":"Qiu","year":"2015"},{"issue":"1","key":"10.1016\/j.mcn.2025.104010_bb0755","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.apsb.2023.07.025","article-title":"Advanced nano-based strategies for mRNA tumor vaccine","volume":"14","author":"Qu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.mcn.2025.104010_bb0760","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.ircmb.2022.04.007","article-title":"mRNA-based therapies: preclinical and clinical applications","volume":"372","author":"Qureischi","year":"2022","journal-title":"Int. Rev. Cell Mol. Biol."},{"issue":"8","key":"10.1016\/j.mcn.2025.104010_bb0765","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nrn3234","article-title":"Emerging roles of non-coding RNAs in brain evolution, development, plasticity and disease","volume":"13","author":"Qureshi","year":"2012","journal-title":"Nat. Rev. Neurosci."},{"issue":"3","key":"10.1016\/j.mcn.2025.104010_bb0770","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3934\/Neuroscience.2023017","article-title":"Depletion of dopamine in Parkinson's disease and relevant therapeutic options: a review of the literature","volume":"10","author":"Ramesh","year":"2023","journal-title":"AIMS Neurosci."},{"issue":"1","key":"10.1016\/j.mcn.2025.104010_bb0775","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrm2085","article-title":"Illuminating the silence: understanding the structure and function of small RNAs","volume":"8","author":"Rana","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.mcn.2025.104010_bb0785","doi-asserted-by":"crossref","DOI":"10.3389\/fpls.2021.641351","article-title":"Coding of non-coding RNA: insights into the regulatory functions of Pri-MicroRNA-encoded peptides in plants","volume":"12","author":"Ren","year":"2021","journal-title":"Front. Plant Sci."},{"key":"10.1016\/j.mcn.2025.104010_bb5000","series-title":"Systems Biology of RNA Binding Proteins","first-page":"303","article-title":"Antisense oligonucleotide-based therapies for diseases caused by pre-mRNA processing defects","author":"Rigo","year":"2014"},{"issue":"9","key":"10.1016\/j.mcn.2025.104010_bb0790","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13091397","article-title":"New RNA-based breakthroughs in Alzheimer\u2019s disease diagnosis and therapeutics","volume":"13","author":"Riscado","year":"2021","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.mcn.2025.104010_bb0795","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.2174\/1567205013666160622112234","article-title":"The long non-coding RNAs in neurodegenerative diseases: novel mechanisms of pathogenesis","volume":"13","author":"Riva","year":"2016","journal-title":"Curr. Alzheimer Res."},{"issue":"10","key":"10.1016\/j.mcn.2025.104010_bb0800","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.mcn.2025.104010_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagrm.2019.194419","article-title":"The how and why of lncRNA function: an innate immune perspective","volume":"1863","author":"Robinson","year":"2020","journal-title":"Biochim. Biophys. Acta - Gene Regul. Mech."},{"issue":"13","key":"10.1016\/j.mcn.2025.104010_bb0810","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241311022","article-title":"Are therapies that target \u03b1-synuclein effective at halting Parkinson\u2019s disease progression? A systematic review","volume":"24","author":"Rodger","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.mcn.2025.104010_bb0815","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.20546\/ijcmas.2020.909.384","article-title":"RNA interference (RNAi) and response of plant cells to double stranded RNA (dsRNA)","volume":"9","author":"Routhu","year":"2020","journal-title":"Int. J. Curr. Microbiol. App. Sci."},{"issue":"3","key":"10.1016\/j.mcn.2025.104010_bb0820","doi-asserted-by":"crossref","DOI":"10.3390\/genes13030425","article-title":"Role of miRNAs in neurodegeneration: from disease cause to tools of biomarker discovery and therapeutics","volume":"13","author":"Roy","year":"2022","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.mcn.2025.104010_bb0825","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/17460441.2024.2440095","article-title":"Evolution of antisense oligonucleotides: navigating nucleic acid chemistry and delivery challenges","volume":"20","author":"Ruchi","year":"2025","journal-title":"Expert Opin. Drug Discovery"},{"issue":"8","key":"10.1016\/j.mcn.2025.104010_bb0830","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11910-024-01345-y","article-title":"Huntington\u2019s disease: latest frontiers in therapeutics","volume":"24","author":"Saade","year":"2024","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.mcn.2025.104010_bb0835","series-title":"Evidence-Based Neurological Disorders","first-page":"383","article-title":"Modern therapeutic approaches of neurological disorders: current insights and future perspectives","author":"Saha","year":"2024"},{"issue":"10","key":"10.1016\/j.mcn.2025.104010_bb0840","doi-asserted-by":"crossref","DOI":"10.3390\/ph13100294","article-title":"Overcoming barriers for siRNA therapeutics: from bench to bedside","volume":"13","author":"Sajid","year":"2020","journal-title":"Pharmaceuticals"},{"issue":"9","key":"10.1016\/j.mcn.2025.104010_bb0845","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/cbin.11841","article-title":"siRNA-based nanotherapeutics as emerging modalities for immune-mediated diseases: a preliminary review","volume":"46","author":"Sargazi","year":"2022","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.mcn.2025.104010_bb0850","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.cca.2012.08.013","article-title":"BACE1 in Alzheimer\u2019s disease","volume":"414","author":"Sathya","year":"2012","journal-title":"Clin. Chim. Acta"},{"issue":"5","key":"10.1016\/j.mcn.2025.104010_bb0855","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.3390\/ijms25052698","article-title":"New insights into oxidative stress and inflammatory response in neurodegenerative diseases","volume":"25","author":"Scarian","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.mcn.2025.104010_bb0860","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2018.09.011","article-title":"Primary transcripts: from the discovery of RNA processing to current concepts of gene expression-review","volume":"373","author":"Scherrer","year":"2018","journal-title":"Exp. Cell Res."},{"issue":"6","key":"10.1016\/j.mcn.2025.104010_bb0865","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","article-title":"Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases","volume":"94","author":"Schoch","year":"2017","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.mcn.2025.104010_bb0870","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/vaccines6020020","article-title":"New kids on the block: RNA-based influenza virus vaccines","volume":"6","author":"Scorza","year":"2018","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.mcn.2025.104010_bb0875","doi-asserted-by":"crossref","DOI":"10.3390\/v15030713","article-title":"Gene therapy for \u03b2-hemoglobinopathies: from discovery to clinical trials","volume":"15","author":"Segura","year":"2023","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.mcn.2025.104010_bb0880","doi-asserted-by":"crossref","DOI":"10.3390\/biology14010093","article-title":"DICER1: the Argonaute endonuclease family member and its role in pediatric and youth pathology","volume":"14","author":"Sergi","year":"2025","journal-title":"Biology"},{"issue":"3","key":"10.1016\/j.mcn.2025.104010_bb0885","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031469","article-title":"Trials and tribulations of MicroRNA therapeutics","volume":"25","author":"Seyhan","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mcn.2025.104010_bb0890","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117465","article-title":"Innovative lipid nanoparticles: a cutting-edge approach for potential renal cell carcinoma therapeutics","volume":"180","author":"Shahzad","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.mcn.2025.104010_bb0895","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2024.105685","article-title":"Regulatory roles of microRNAs in modulating mitochondrial dynamics, amyloid beta fibrillation, microglial activation, and cholinergic signaling: implications for Alzheimer\u2019s disease pathogenesis","volume":"161","author":"Sharma","year":"2024","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.mcn.2025.104010_bb0900","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jconrel.2024.03.056","article-title":"mRNA therapies: pioneering a new era in rare genetic disease treatment","volume":"369","author":"Shen","year":"2024","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.mcn.2025.104010_bb0905","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1158\/0008-5472.CAN-14-2568","article-title":"Signaling-mediated regulation of MicroRNA processing","volume":"75","author":"Shen","year":"2015","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.mcn.2025.104010_bb0910","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","article-title":"Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.mcn.2025.104010_bb0915","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1021\/acs.chemrev.3c00611","article-title":"Chemically modified platforms for better RNA therapeutics","volume":"124","author":"Shi","year":"2024","journal-title":"Chem. Rev."},{"issue":"3","key":"10.1016\/j.mcn.2025.104010_bb0920","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/cmdc.200900444","article-title":"Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook","volume":"5","author":"Shukla","year":"2010","journal-title":"ChemMedChem"},{"issue":"9","key":"10.1016\/j.mcn.2025.104010_bb0925","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3390\/ijms17091440","article-title":"Surface modified multifunctional and stimuli responsive nanoparticles for drug targeting: current status and uses","volume":"17","author":"Siafaka","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mcn.2025.104010_bb0930","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102002","article-title":"The hidden players: shedding light on the significance of post-translational modifications and miRNAs in Alzheimer\u2019s disease development","volume":"90","author":"Singh","year":"2023","journal-title":"Ageing Res. Rev."},{"issue":"4","key":"10.1016\/j.mcn.2025.104010_bb0935","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2174\/1389200224666230608110349","article-title":"Structure of the blood brain barrier and its role in the transporters for the movement of substrates across the barriers","volume":"24","author":"Singh","year":"2023","journal-title":"Curr. Drug Metab."},{"issue":"4","key":"10.1016\/j.mcn.2025.104010_bb0940","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/10611860600650086","article-title":"Endocytosis at the blood-brain barrier: from basic understanding to drug delivery strategies","volume":"14","author":"Smith","year":"2006","journal-title":"J. Drug Target."},{"key":"10.1016\/j.mcn.2025.104010_bb0945","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.msec.2018.10.069","article-title":"Reconstructing nanofibers from natural polymers using surface functionalization approaches for applications in tissue engineering, drug delivery and biosensing devices","volume":"94","author":"Sofi","year":"2019","journal-title":"Mater. Sci. Eng. C"},{"issue":"2","key":"10.1016\/j.mcn.2025.104010_bb0950","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/bph.16412","article-title":"Targeting noncoding RNAs to treat atherosclerosis","volume":"182","author":"Sopi\u0107","year":"2025","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.mcn.2025.104010_bb0955","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41593-018-0235-9","article-title":"Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases","volume":"21","author":"Soto","year":"2018","journal-title":"Nat. Neurosci."},{"issue":"21","key":"10.1016\/j.mcn.2025.104010_bb0960","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2023114760","article-title":"RNA-based medicine: from molecular mechanisms to therapy","volume":"42","author":"Sparmann","year":"2023","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.mcn.2025.104010_bb0965","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","article-title":"Gene regulation by long non-coding RNAs and its biological functions","volume":"22","author":"Statello","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.mcn.2025.104010_bb5005","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","article-title":"FDA-approved oligonucleotide therapies in 2017","volume":"25","author":"Stein","year":"2017","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.mcn.2025.104010_bb0975","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/14728222.2022.2066519","article-title":"Targeting fetal hemoglobin expression to treat \u03b2 hemoglobinopathies","volume":"26","author":"Steinberg","year":"2022","journal-title":"Expert Opin. Ther. Targets"},{"issue":"4","key":"10.1016\/j.mcn.2025.104010_bb0980","article-title":"Genetic variants in mRNA untranslated regions","volume":"9","author":"Steri","year":"2018","journal-title":"Wiley Interdiscip. Rev.: RNA"},{"issue":"5","key":"10.1016\/j.mcn.2025.104010_bb0985","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1021\/mp300518e","article-title":"Physiology of blood\u2013brain interfaces in relation to brain disposition of small compounds and macromolecules","volume":"10","author":"Strazielle","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.mcn.2025.104010_bb0990","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1034072","article-title":"miRNA and antisense oligonucleotide-based \u03b1-synuclein targeting as disease-modifying therapeutics in Parkinson\u2019s disease","volume":"13","author":"Suvarna","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.mcn.2025.104010_bb0995","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","article-title":"Huntingtin lowering strategies for disease modification in Huntington\u2019s disease","volume":"101","author":"Tabrizi","year":"2019","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.mcn.2025.104010_bb1000","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41573-019-0049-9","article-title":"Therapies for rare diseases: therapeutic modalities, progress and challenges ahead","volume":"19","author":"Tambuyzer","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"22","key":"10.1016\/j.mcn.2025.104010_bb1010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252212284","article-title":"Recent advances and prospects in RNA drug development","volume":"25","author":"Tani","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mcn.2025.104010_bb1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102327","article-title":"ncRNAs and their impact on dopaminergic neurons: autophagy pathways in Parkinson\u2019s disease","volume":"98","author":"Thapa","year":"2024","journal-title":"Ageing Res. Rev."},{"issue":"2","key":"10.1016\/j.mcn.2025.104010_bb1020","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14020342","article-title":"Delivery of oligonucleotides: efficiency with lipid conjugation and clinical outcome","volume":"14","author":"Tran","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.mcn.2025.104010_bb1025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-021-00755-1","article-title":"The regulatory roles of microRNAs toward pathogenesis and treatments in Huntington\u2019s disease","volume":"28","author":"Tung","year":"2021","journal-title":"J. Biomed. Sci."},{"issue":"11","key":"10.1016\/j.mcn.2025.104010_bb1030","doi-asserted-by":"crossref","DOI":"10.3390\/ph16111513","article-title":"Huntington\u2019s disease drug development: a phase 3 pipeline analysis","volume":"16","author":"Van de Roovaart","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.mcn.2025.104010_bb1035","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12020102","article-title":"Opportunities and challenges in the delivery of mRNA-based vaccines","volume":"12","author":"Wadhwa","year":"2020","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.mcn.2025.104010_bb1040","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106829","article-title":"microRNA-132 regulates gene expression programs involved in microglial homeostasis","volume":"26","author":"Walgrave","year":"2023","journal-title":"iScience"},{"issue":"5","key":"10.1016\/j.mcn.2025.104010_bb1045","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29051124","article-title":"Aptamer technologies in neuroscience, neuro-diagnostics and neuro-medicine development","volume":"29","author":"Wang","year":"2024","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.mcn.2025.104010_bb1050","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.molcel.2011.08.018","article-title":"Molecular mechanisms of long noncoding RNAs","volume":"43","author":"Wang","year":"2011","journal-title":"Mol. Cell"},{"issue":"18","key":"10.1016\/j.mcn.2025.104010_bb1055","doi-asserted-by":"crossref","DOI":"10.7150\/thno.62642","article-title":"Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry","volume":"11","author":"Wang","year":"2021","journal-title":"Theranostics"},{"issue":"23","key":"10.1016\/j.mcn.2025.104010_bb1060","article-title":"Effect of lncRNA WT1-AS regulating WT1 on oxidative stress injury and apoptosis of neurons in Alzheimer\u2019s disease via inhibition of the miR-375\/SIX4 axis","volume":"12","author":"Wang","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"7200","key":"10.1016\/j.mcn.2025.104010_bb1065","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nature06992","article-title":"Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription","volume":"454","author":"Wang","year":"2008","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.mcn.2025.104010_bb1070","article-title":"LncRNA XIST knockdown attenuates A\u03b225-35-induced toxicity, oxidative stress, and apoptosis in primary cultured rat hippocampal neurons by targeting miR-132","volume":"11","author":"Wang","year":"2018","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"2","key":"10.1016\/j.mcn.2025.104010_bb1075","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.166038","article-title":"Dicer1 promotes A\u03b2 clearance via blocking B2 RNA-mediated repression of apolipoprotein E","volume":"1867","author":"Wang","year":"2021","journal-title":"Biochim. Biophys. Acta - Mol. Basis Dis."},{"issue":"13","key":"10.1016\/j.mcn.2025.104010_bb1080","doi-asserted-by":"crossref","DOI":"10.3390\/nano12132140","article-title":"Applications of various types of nanomaterials for the treatment of neurological disorders","volume":"12","author":"Waris","year":"2022","journal-title":"Nanomaterials"},{"issue":"10427","key":"10.1016\/j.mcn.2025.104010_bb1085","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.mcn.2025.104010_bb1090","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington\u2019s disease","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.mcn.2025.104010_bb1095","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrg3978","article-title":"Knocking down disease: a progress report on siRNA therapeutics","volume":"16","author":"Wittrup","year":"2015","journal-title":"Nat. Rev. Genet."},{"issue":"15","key":"10.1016\/j.mcn.2025.104010_bb1100","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1093\/hmg\/ddt164","article-title":"De-repression of FOXO3a death axis by microRNA-132 and-212 causes neuronal apoptosis in Alzheimer\u2019s disease","volume":"22","author":"Wong","year":"2013","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.mcn.2025.104010_bb1105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.0030109","article-title":"Modulating the expression of disease genes with RNA-based therapy","volume":"3","author":"Wood","year":"2007","journal-title":"PLoS Genet."},{"key":"10.1016\/j.mcn.2025.104010_bb1110","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1007\/s00415-012-6413-x","article-title":"Cerebrospinal fluid and lumbar puncture: a practical review","volume":"259","author":"Wright","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.mcn.2025.104010_bb1120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175956","article-title":"Development of microRNA-based therapeutics for central nervous system diseases","volume":"956","author":"Xia","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.mcn.2025.104010_bb1125","article-title":"RNA-based therapies in hepatocellular carcinoma: state of the art and clinical perspectives","volume":"10","author":"Xing","year":"2024","journal-title":"Hepatoma Res."},{"issue":"2","key":"10.1016\/j.mcn.2025.104010_bb1130","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00439-019-01970-5","article-title":"Translating cancer genomics into precision medicine with artificial intelligence: applications, challenges and future perspectives","volume":"138","author":"Xu","year":"2019","journal-title":"Hum. Genet."},{"key":"10.1016\/j.mcn.2025.104010_bb1135","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106614","article-title":"Long noncoding RNA GAS5 promotes microglial inflammatory response in Parkinson\u2019s disease by regulating NLRP3 pathway through sponging miR-223-3p","volume":"85","author":"Xu","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.mcn.2025.104010_bb1140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114298","article-title":"Exosome-based macromolecular neurotherapeutic drug delivery approaches in overcoming the blood-brain barrier for treating brain disorders","volume":"199","author":"Yadav","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.mcn.2025.104010_bb1145","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2022.01.008","article-title":"Non-viral vectors for RNA delivery","volume":"342","author":"Yan","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.mcn.2025.104010_bb1150","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1039\/D4NR04394D","article-title":"Recent advances in mRNA-based therapeutics for neurodegenerative diseases and brain tumors","volume":"17","author":"Yang","year":"2025","journal-title":"Nanoscale"},{"issue":"sup1","key":"10.1016\/j.mcn.2025.104010_bb1155","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/15476286.2021.1950465","article-title":"Non-coding RNAs: the extensive and interactive regulators of the blood-brain barrier permeability","volume":"18","author":"Yang","year":"2021","journal-title":"RNA Biol."},{"issue":"15","key":"10.1016\/j.mcn.2025.104010_bb1160","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202202688","article-title":"Polymer-based mRNA delivery strategies for advanced therapies","volume":"12","author":"Yang","year":"2023","journal-title":"Adv. Healthc. Mater."},{"issue":"8","key":"10.1016\/j.mcn.2025.104010_bb1165","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-018-0821-5","article-title":"A lincRNA-p21\/miR-181 family feedback loop regulates microglial activation during systemic LPS-and MPTP-induced neuroinflammation","volume":"9","author":"Ye","year":"2018","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.mcn.2025.104010_bb1170","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/nrg3763","article-title":"Non-viral vectors for gene-based therapy","volume":"15","author":"Yin","year":"2014","journal-title":"Nat. Rev. Genet."},{"issue":"8","key":"10.1016\/j.mcn.2025.104010_bb1175","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1517\/17425247.2010.501792","article-title":"Gateways for the intracellular access of nanocarriers: a review of receptor-mediated endocytosis mechanisms and of strategies in receptor targeting","volume":"7","author":"Zaki","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.mcn.2025.104010_bb1180","series-title":"Handbook of Cancer and Immunology","first-page":"1","article-title":"Advancing precision medicine: integrating next-generation sequencing and tumor markers for early cancer detection and personalized treatment","author":"Zalli","year":"2023"},{"key":"10.1016\/j.mcn.2025.104010_bb1185","article-title":"Role and regulatory mechanism of microRNA mediated neuroinflammation in neuronal system diseases","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.mcn.2025.104010_bb1190","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1007\/s12035-018-1299-y","article-title":"Silencing of long noncoding RNA SOX21-AS1 relieves neuronal oxidative stress injury in mice with Alzheimer\u2019s disease by upregulating FZD3\/5 via the Wnt signaling pathway","volume":"56","author":"Zhang","year":"2019","journal-title":"Mol. Neurobiol."},{"issue":"6","key":"10.1016\/j.mcn.2025.104010_bb1200","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/01616412.2018.1548747","article-title":"The long-noncoding RNA NEAT1 is a novel target for Alzheimer\u2019s disease progression via miR124\/BACE1 axis","volume":"41","author":"Zhao","year":"2019","journal-title":"Neurol. Res."},{"issue":"7","key":"10.1016\/j.mcn.2025.104010_bb1205","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1172\/JCI64502","article-title":"shRNA targeting \u03b1-synuclein prevents neurodegeneration in a Parkinson\u2019s disease model","volume":"125","author":"Zharikov","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.mcn.2025.104010_bb1210","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11033-023-08968-3","article-title":"Current non-invasive strategies for brain drug delivery: overcoming blood-brain barrier transport","volume":"51","author":"Zheng","year":"2024","journal-title":"Mol. Biol. Rep."},{"issue":"3","key":"10.1016\/j.mcn.2025.104010_bb1215","doi-asserted-by":"crossref","DOI":"10.3390\/ph15030358","article-title":"Targeted drug delivery to the central nervous system using extracellular vesicles","volume":"15","author":"Zhou","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.mcn.2025.104010_bb1225","article-title":"Long non-coding RNAs in pathogenesis of neurodegenerative diseases","volume":"9","author":"Zhou","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"7","key":"10.1016\/j.mcn.2025.104010_bb1230","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41419-022-05075-2","article-title":"RNA-based therapeutics: an overview and prospectus","volume":"13","author":"Zhu","year":"2022","journal-title":"Cell Death Dis."}],"container-title":["Molecular and Cellular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104474312500020X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104474312500020X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:31:24Z","timestamp":1749169884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104474312500020X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":238,"alternative-id":["S104474312500020X"],"URL":"https:\/\/doi.org\/10.1016\/j.mcn.2025.104010","relation":{},"ISSN":["1044-7431"],"issn-type":[{"value":"1044-7431","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RNA-based therapies for neurodegenerative disease: Targeting molecular mechanisms for disease modification","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcn.2025.104010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104010"}}